Nanexa Shares Soar on €1.17 Billion Novo Nordisk Deal for Injection Technology
Nanexa said the pact could bring up to €1.17 billion, including upfront, milestone and sales payments, as Novo targets monthly and quarterly dosing.
- On Friday, Swedish drug-delivery company Nanexa shares surged after signing a global licensing deal with Novo Nordisk worth up to about €1.17 billion , covering long-acting injectable drugs for obesity, type 2 diabetes, and other cardiometabolic diseases.
- Novo gained exclusive rights to use Nanexa's PharmaShell technology in up to five development programs, targeting formulations administered monthly or quarterly, "reducing the frequency of injections for chronic treatments," the companies said.
- The deal includes an upfront payment and milestones totaling €615 million, with "Nanexa will receive a low single-digit percentage in royalties on global sales of products developed under the agreement."
- Nanexa shares soared around 122% in early Friday trading, reaching their highest levels in more than five years as Novo will lead global development and commercialization of products.
- CEO David Westburg said the agreement "provides a strong foundation for expanding PharmaShell into additional therapeutic areas," while Chair Ando noted it grants the company "considerable financial strength" for long-term growth.
25 Articles
25 Articles
Novo has agreed to pay up to $1.3 billion to license and develop the medicine management technology of the Swedish pharmaceutical company Nanexa, in an agreement that can reduce the frequency with which patients need to inject their medications for obesity and diabetes. Exclusive material for subscribers. To have full access, access the link of the subject and register.
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D24&w=64&q=75){kind=small}
Nanexa Shares More Than Double After €1.17 Billion Novo Nordisk Licensing Deal
Swedish drug-delivery company Nanexa saw its shares jump about 122% after announcing a licensing agreement with Novo Nordisk worth up to €1.17 billion ($1.33 billion). The deal gives Novo exclusive rights to Nanexa’s PharmaShell technology for as many as five development programs focused on longer-acting injectable medicines.
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology - Regional Media News
Sept 25 (Reuters) - Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about €1.17 billion ($1.33 billion). The agreement, announced after the market closed on [...]
The Manufacturer of Ozempic Responds to Its Stock Market Collapse with an Agreement of 1,165 Million
Novo Nordisk, the Danish laboratory behind top-selling medicines such as Ozempic and Wegovy, has moved a tab to reinforce its portfolio of new-generation treatments with an agreement of up to €1,165 million with Swedish pharmaceutical company Nanexa. The pact comes just a few days after Novo’s shares plummet on the stock market after the presentation of its growth strategy until 2030, in a context marked by competitive pressure on the obesity ma…
Nanexa shares soar on €1.17 billion Novo Nordisk deal for injection technology
Sept 25 (Reuters) - Shares in Swedish drug-delivery company Nanexa more than doubled their value in early Friday trading after it signed a global licensing deal with Novo Nordisk worth up to about €1.17 billion ($1.33 billion). The agreement, announc...
Coverage Details
Bias Distribution
- 62% of the sources lean Right
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
